Merck & Co., Inc. $MRK Position Boosted by Capital Analysts LLC

Capital Analysts LLC grew its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 10.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 73,785 shares of the company’s stock after purchasing an additional 6,787 shares during the period. Capital Analysts LLC’s holdings in Merck & Co., Inc. were worth $7,766,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in MRK. Kingdom Financial Group LLC. bought a new position in shares of Merck & Co., Inc. during the 4th quarter valued at about $25,000. United Financial Planning Group LLC bought a new position in shares of Merck & Co., Inc. during the 3rd quarter valued at about $31,000. High Note Wealth LLC boosted its position in shares of Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after purchasing an additional 109 shares in the last quarter. Tucker Asset Management LLC bought a new position in shares of Merck & Co., Inc. during the 4th quarter valued at about $34,000. Finally, Wealth Watch Advisors INC bought a new position in shares of Merck & Co., Inc. during the 3rd quarter valued at about $34,000. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Gilead reported positive Phase 3 results for their once-weekly HIV regimen islatravir/lenacapavir, meeting the primary efficacy endpoint in both studies and moving the program closer to regulatory filings. Article: Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
• Positive Sentiment: The HIV data could strengthen Merck’s long-term pipeline and add a potential new growth driver if the once-weekly treatment wins approval and commercialization proceeds as expected. Article: Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
• Neutral Sentiment: Merck also presented at the Goldman Sachs 47th Annual Global Healthcare Conference, which typically reinforces management’s strategy and pipeline commentary but does not by itself change fundamentals. Article: Merck & Co., Inc. (MRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Merck’s collaboration with The Hashgraph Group on an EU digital product passport for regulated supply chains is strategically interesting, but it is unlikely to have a near-term material impact on earnings. Article: The Hashgraph Group and Merck Introduce EU Digital Product Passport on Hedera for Regulated Supply Chains
• Negative Sentiment: Merck and Gilead discontinued a Phase 3 non-small cell lung cancer study after it failed to show a statistically significant benefit, which removes one potential oncology catalyst and highlights clinical risk in the pipeline. Article: Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
• Negative Sentiment: Reuters also reported Merck is exploring treatment options for a rare Ebola strain, which may reflect additional research effort but could carry uncertainty around development timing and commercial value. Article: Merck (MRK) Explores Treatment Options for Rare Ebola Strain, Reuters Reports

Merck & Co., Inc. Price Performance

NYSE MRK opened at $119.54 on Wednesday. The company has a 50 day simple moving average of $116.56 and a 200-day simple moving average of $112.85. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The firm has a market capitalization of $295.24 billion, a price-to-earnings ratio of 33.67, a price-to-earnings-growth ratio of 2.69 and a beta of 0.21. Merck & Co., Inc. has a 52-week low of $76.66 and a 52-week high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm’s revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities research analysts predict that Merck & Co., Inc. will post 5.17 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be given a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio is 95.77%.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Barclays assumed coverage on shares of Merck & Co., Inc. in a report on Friday, February 20th. They issued an “overweight” rating and a $140.00 target price for the company. Citigroup assumed coverage on shares of Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 target price for the company. Wall Street Zen upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday. UBS Group raised their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 target price for the company in a report on Friday, February 13th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat.com, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and an average price target of $128.18.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.